Dennis L Winger

CIK 1222645 · Senior Vice President and CFO · last filed 2018-08-21

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$17.41M
Companies
7
Total Filings
114
Lifetime Open-Market Net
-$16.28M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

CRA price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Related Filers
Pacira BioSciences, Inc. — 7 joint filings, latest 2017-06-16
VERTEX PHARMACEUTICALS INC / MA — 7 joint filings, latest 2012-03-12
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
NKTR Director 3,183 $38.65 $123.0K -$3.83M 16 2018-08-21
ARAY Director 162,181 $0.13 $21.7K $85.9K 14 2017-12-04
PCRX Director 7,490 $36.34 $272.2K $250.1K 5 2017-06-16
VRTX Director 31,750 $535.17 $16.99M $250.5K 5 2012-03-12
CEPHALON INC (CEPH) Delisted Director — — — $0 6 2011-10-17
CELL GENESYS INC (CEGE) Delisted Director 0 — — $0 4 2009-10-15
APPLIED BIOSYSTEMS INC. (CRA) Delisted Senior Vice President and CFO 75,371 — — -$13.04M 60 2008-02-08

Recent Filings · Page 2 of 12

114 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2016-09-19 NKTR Exer (M) +15,000 $0 EDGAR
2016-06-17 PCRX Grant (A) +1,488 $0 EDGAR
2015-12-02 ARAY Grant (A) +17,045 $0 EDGAR
2015-11-24 ARAY Tax (F) −6,967 -$47.4K EDGAR
2015-09-17 NKTR Grant (A) — $0 EDGAR
2015-06-05 PCRX Grant (A) +2,000 $0 EDGAR
2014-12-08 PCRX Buy (P) +2,645 $250.1K EDGAR
2014-12-02 ARAY Mixed +11,401 -$40.0K EDGAR
2014-09-25 NKTR Grant (A) — $0 EDGAR
2013-12-03 ARAY Grant (A) +15,037 $0 EDGAR
Showing 11–20 of 114
Page 2 of 12
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.